SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-757991
Filing Date
2016-11-03
Accepted
2016-11-03 07:01:32
Documents
71
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d254310d10q.htm 10-Q 530071
2 EX-31.1 d254310dex311.htm EX-31.1 9394
3 EX-31.2 d254310dex312.htm EX-31.2 9473
4 EX-32.1 d254310dex321.htm EX-32.1 5679
  Complete submission text file 0001193125-16-757991.txt   3964258

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20160930.xml EX-101.INS 681919
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20160930.xsd EX-101.SCH 54673
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20160930_cal.xml EX-101.CAL 65524
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20160930_def.xml EX-101.DEF 305706
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20160930_lab.xml EX-101.LAB 401944
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20160930_pre.xml EX-101.PRE 363614
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 161970100
SIC: 2834 Pharmaceutical Preparations